← FDA ENFORCEMENT
D-0506-2026Class II

Wells Pharma of Houston LLC

Recalling firm
Wells Pharma of Houston LLC
Product type
Drug
Status
Ongoing
Report date
2026-05-06
Distribution
U.S. Nationwide.
Firm state
TX
Product quantity
150 syringes
Initiated by
Voluntary: Firm initiated
SPEQ quality domain
Risk Management & CAPA
Reason for recall

cGMP deviations.

Product description

fentaNYL Citrate Injectable Solution in 0.9% Sodium Chloride, 1000 mcg/50mL (20 mcg per mL), well pharma of Houston, NDC 73702-203-65.

Code / lot info

Lot 022326203650432; Exp Date 06/25/2026

Other recalls SPEQ maps to Risk Management & CAPA
2026-07-22Class IAbiomed, Inc.2026-07-22Class IAbiomed, Inc.2026-07-22Class IAbiomed, Inc.2026-07-22Class IAbiomed, Inc.
See all Risk Management & CAPA recalls →

Data: U.S. FDA openFDA enforcement API. Recall details are as reported by the FDA. The quality-domain mapping and severity are a SPEQ editorial interpretation of the recall reason, not an official FDA classification.